In future studies, we anticipate a higher dosage of TRAIL with minimal injections will yield more significant results, as evidenced by our 2019 study using TRAIL-resistant mouse breast cancer cells (2.5 mg/kg TRAIL per injection) [36]. The gene discussed is TNFSF10; the disease is breast cancer.